Arrowhead Pharmaceuticals (ARWR) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $55.90, -4.44% vs the prior close of $58.50.
- Volume 1.77M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ARWR slides 4.4% to $55.90, a 6-month low. Closed at $55.90, -4.44% vs the prior close of $58.50. Day range $55.83–$58.45, opened at $58.45.
ARWR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ARWR slides 4.4% to $55.90, a 6-month low
- Closed at $55.90, -4.44% vs the prior close of $58.50. Day range $55.83–$58.45, opened at $58.45.
- Volume was 1.77M shares, 1.0x its 50-day average of 1.80M.
- Price is -26.0% vs its 50-day average ($75.56) and -22.5% vs its 200-day average ($72.09).
- 52-week range $36.57–$95.49; today's close sits at 33% of that range, 41.5% below the 52-week high.
Oct 15, 2026 — ARWR ends flat (+0.2%) to $58.50
- Closed at $58.50, +0.22% vs the prior close of $58.37. Day range $57.40–$59.40, opened at $58.50.
- Volume was 2.01M shares, 1.1x its 50-day average of 1.79M.
- Price is -23.2% vs its 50-day average ($76.15) and -18.9% vs its 200-day average ($72.15).
- 52-week range $36.02–$95.49; today's close sits at 38% of that range, 38.7% below the 52-week high.
Oct 14, 2026 — ARWR rises 0.4% to $58.37 on 2.4x normal volume
- Closed at $58.37, +0.41% vs the prior close of $58.13. Day range $57.15–$60.53, opened at $58.48.
- Volume was 4.16M shares, 2.4x its 50-day average of 1.75M — unusually heavy trading.
- Price is -23.9% vs its 50-day average ($76.72) and -19.2% vs its 200-day average ($72.20).
- 52-week range $34.61–$95.49; today's close sits at 39% of that range, 38.9% below the 52-week high.
Oct 13, 2026 — ARWR slides 4.3% to $58.13, a 6-month low
- Closed at $58.13, -4.28% vs the prior close of $60.73. Day range $58.08–$60.73, opened at $60.04.
- Volume was 2.26M shares, 1.3x its 50-day average of 1.73M.
- Price is -24.8% vs its 50-day average ($77.35) and -19.6% vs its 200-day average ($72.26).
- 52-week range $34.61–$95.49; today's close sits at 39% of that range, 39.1% below the 52-week high.
Oct 12, 2026 — ARWR slides 3.2% to $60.73, a 6-month low
- Closed at $60.73, -3.22% vs the prior close of $62.75. Day range $60.48–$62.50, opened at $62.49.
- Volume was 1.19M shares, 0.7x its 50-day average of 1.74M.
- Price is -22.0% vs its 50-day average ($77.90) and -16.0% vs its 200-day average ($72.32).
- 52-week range $34.61–$95.49; today's close sits at 43% of that range, 36.4% below the 52-week high.
Oct 9, 2026 — ARWR jumps 3.3% to $62.75
- Closed at $62.75, +3.31% vs the prior close of $60.74. Day range $60.44–$62.99, opened at $60.72.
- Volume was 2.77M shares, 1.6x its 50-day average of 1.71M.
- Price is -19.9% vs its 50-day average ($78.38) and -13.3% vs its 200-day average ($72.37).
- 52-week range $34.61–$95.49; today's close sits at 46% of that range, 34.3% below the 52-week high.
Oct 8, 2026 — ARWR dips 1.2% to $60.74, a 6-month low, 7 down days in a row
- Closed at $60.74, -1.20% vs the prior close of $61.48. Day range $59.21–$61.13, opened at $60.54.
- Volume was 1.78M shares, 1.0x its 50-day average of 1.71M.
- Price is -23.0% vs its 50-day average ($78.87) and -16.1% vs its 200-day average ($72.40).
- 52-week range $34.61–$95.49; today's close sits at 43% of that range, 36.4% below the 52-week high.
- That makes 7 straight losses.
Oct 7, 2026 — ARWR ends flat (-0.1%) to $61.48, a 6-month low, 6 down days in a row
- Closed at $61.48, -0.10% vs the prior close of $61.54. Day range $60.78–$62.75, opened at $61.63.
- Volume was 1.82M shares, 1.1x its 50-day average of 1.71M.
- Price is -22.6% vs its 50-day average ($79.38) and -15.1% vs its 200-day average ($72.43).
- 52-week range $34.61–$95.49; today's close sits at 44% of that range, 35.6% below the 52-week high.
- That makes 6 straight losses.
Oct 6, 2026 — ARWR dips 1.3% to $61.54, a 3-month low, 5 down days in a row
- Closed at $61.54, -1.30% vs the prior close of $62.35. Day range $60.56–$63.19, opened at $62.86.
- Volume was 1.68M shares, 1.0x its 50-day average of 1.72M.
- Price is -22.9% vs its 50-day average ($79.87) and -15.1% vs its 200-day average ($72.46).
- 52-week range $34.61–$95.49; today's close sits at 44% of that range, 35.6% below the 52-week high.
- That makes 5 straight losses.
Oct 5, 2026 — ARWR dips 2.9% to $62.35, a 3-month low, 4 down days in a row
- Closed at $62.35, -2.87% vs the prior close of $64.19. Day range $62.22–$64.76, opened at $64.76.
- Volume was 2.25M shares, 1.3x its 50-day average of 1.72M.
- Price is -22.4% vs its 50-day average ($80.35) and -14.0% vs its 200-day average ($72.48).
- 52-week range $34.61–$95.49; today's close sits at 46% of that range, 34.7% below the 52-week high.
- That makes 4 straight losses.
Oct 2, 2026 — ARWR dips 0.9% to $64.19, a 3-month low, 3 down days in a row
- Closed at $64.19, -0.93% vs the prior close of $64.79. Day range $63.99–$66.16, opened at $65.57.
- Volume was 1.49M shares, 0.9x its 50-day average of 1.73M.
- Price is -20.6% vs its 50-day average ($80.81) and -11.4% vs its 200-day average ($72.49).
- 52-week range $34.47–$95.49; today's close sits at 49% of that range, 32.8% below the 52-week high.
- That makes 3 straight losses.
ARWR latest news & SEC filings
Every SEC filing by or about ARWR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Olukotun Adeoye Y sold 2,000 shares at $86.96 (≈$173.92K) on Aug 18, 2026
- Olukotun Adeoye Y sold 2,000 shares at $86.96 (≈$173.92K) on Aug 18, 2026
- Olukotun Adeoye Y sold 2,000 shares at $86.96 (≈$173.92K) on Aug 18, 2026
- Olukotun Adeoye Y sold 2,000 shares at $86.96 (≈$173.92K) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Perry Michael S sold 11,600 shares at $87.30 (≈$1.01M) on Aug 18, 2026
- Perry Michael S sold 11,600 shares at $87.30 (≈$1.01M) on Aug 18, 2026
- Perry Michael S sold 11,600 shares at $87.30 (≈$1.01M) on Aug 18, 2026
- Perry Michael S sold 11,600 shares at $87.30 (≈$1.01M) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 18, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $75.25M (prior year $27.77M) (+171.0% vs Jun 30, 2025)
- Net income: -$194.28M (prior year -$175.24M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.36 (prior year -$1.26) (loss widened vs Jun 30, 2025)
Jul 31, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 27, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade ARWR
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 5, 2026, Nov 25, 2025. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.14% (largest 6.8%).
- Liquidity: about 2.11M shares (≈$117.85M) trade per day on average.
- 52-week position: $55.90 vs a range of $36.57–$95.49 (33% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Adeoye Y Olukotun sold 2,000 shares on Aug 18, 2026.
- Latest filings: 8-K Aug 4, 2026; 10-Q Aug 4, 2026; 8-K Jun 16, 2026.
- Share count: 141.25M shares outstanding (Jul 30, 2026), +2.2% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ARWR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 58.45 | 58.45 | 55.83 | 55.90 | 1.77M |
| Oct 15, 2026 | 58.50 | 59.40 | 57.40 | 58.50 | 2.01M |
| Oct 14, 2026 | 58.48 | 60.53 | 57.15 | 58.37 | 4.16M |
| Oct 13, 2026 | 60.04 | 60.73 | 58.08 | 58.13 | 2.26M |
| Oct 12, 2026 | 62.49 | 62.50 | 60.48 | 60.73 | 1.19M |
| Oct 9, 2026 | 60.72 | 62.99 | 60.44 | 62.75 | 2.77M |
| Oct 8, 2026 | 60.54 | 61.13 | 59.21 | 60.74 | 1.78M |
| Oct 7, 2026 | 61.63 | 62.75 | 60.78 | 61.48 | 1.82M |
| Oct 6, 2026 | 62.86 | 63.19 | 60.56 | 61.54 | 1.68M |
| Oct 5, 2026 | 64.76 | 64.76 | 62.22 | 62.35 | 2.25M |
| Oct 2, 2026 | 65.57 | 66.16 | 63.99 | 64.19 | 1.49M |
| Oct 1, 2026 | 65.00 | 65.75 | 64.50 | 64.79 | 1.52M |
| Sep 30, 2026 | 66.80 | 66.80 | 65.09 | 65.45 | 1.74M |
| Sep 29, 2026 | 65.46 | 66.83 | 64.57 | 66.25 | 2.87M |
| Sep 28, 2026 | 65.00 | 66.11 | 63.99 | 65.46 | 1.59M |
| Sep 25, 2026 | 66.50 | 67.44 | 65.40 | 65.92 | 1.62M |
| Sep 24, 2026 | 67.00 | 67.45 | 65.46 | 66.07 | 1.63M |
| Sep 23, 2026 | 72.15 | 72.49 | 66.27 | 66.96 | 2.55M |
| Sep 22, 2026 | 68.85 | 72.36 | 68.08 | 71.86 | 3.12M |
| Sep 21, 2026 | 67.46 | 69.26 | 66.06 | 68.79 | 2.35M |
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals (ARWR) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PASADENA, CA. State of incorporation: DE. Fiscal year ends September 30. SEC CIK 879407.
ARWR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Christopher Richard Anzalone | Chief Executive Officer | Jan 5, 2026 |
| Matthew Gregory Cohen | Director | Jun 17, 2026 |
| Mauro Ferrari | Director | Dec 30, 2025 |
| Douglas S Ingram | Director | Dec 18, 2025 |
| Hongbo Lu | Director | May 14, 2026 |
| Adeoye Y Olukotun | Director | Aug 20, 2026 |
| Michael S Perry | Director | Aug 20, 2026 |
| Victoria Vakiener | Director | Dec 23, 2025 |
| William D. Waddill | Director | Dec 23, 2025 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christopher Richard Anzalone | Chief Executive Officer | Jan 5, 2026 |
| Daniel Joseph Apel | Chief Financial Officer | Apr 24, 2026 |
| James C Hamilton | Chief Medical Officer | Apr 24, 2026 |
| Patrick O'Brien | COO | Jan 8, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | Adeoye Y Olukotun | Sale | 2,000 | $86.96 |
| Aug 18, 2026 | Adeoye Y Olukotun | Sale | 2,000 | $86.96 |
| Aug 18, 2026 | Adeoye Y Olukotun | Sale | 2,000 | $86.96 |
| Aug 18, 2026 | Adeoye Y Olukotun | Sale | 2,000 | $86.96 |
| Aug 18, 2026 | Michael S Perry | Sale | 11,600 | $87.30 |
| Aug 18, 2026 | Michael S Perry | Sale | 11,600 | $87.30 |
| Aug 18, 2026 | Michael S Perry | Sale | 11,600 | $87.30 |
| Aug 18, 2026 | Michael S Perry | Sale | 11,600 | $87.30 |
| May 12, 2026 | Hongbo Lu | Sale | 2,970 | $76.88 |
| May 12, 2026 | Hongbo Lu | Sale | 2,970 | $76.88 |
| May 12, 2026 | Hongbo Lu | Sale | 2,970 | $76.88 |
| May 12, 2026 | Hongbo Lu | Sale | 2,970 | $76.88 |
| Apr 23, 2026 | James C Hamilton | Sale | 10,000 | $75.00 |
| Apr 23, 2026 | James C Hamilton | Sale | 10,000 | $75.00 |
| Apr 23, 2026 | James C Hamilton | Sale | 10,000 | $75.00 |
ARWR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Sep 30, 2025 | $829.45M | $-1.63M | -0.01 | $179.55M |
| Sep 30, 2024 | $3.55M | $-599.49M | -5.00 | $-462.85M |
| Sep 30, 2023 | $240.74M | $-205.28M | -1.92 | $-153.89M |
| Sep 30, 2022 | $243.23M | $-176.06M | -1.67 | $-136.13M |
| Sep 30, 2021 | $138.29M | $-140.85M | -1.36 | $171.31M |
Latest balance sheet: total assets $2.11B, total liabilities $—, cash $69.40M (as of Jun 30, 2026).
ARWR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $89.59 |
| May 7, 2026 | 8-K Item 2.02 (results) | $77.95 |
| Feb 5, 2026 | 8-K Item 2.02 (results) | $64.64 |
| Nov 25, 2025 | 8-K Item 2.02 (results) | $46.79 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $16.06 |
| May 12, 2025 | 8-K Item 2.02 (results) | $13.97 |
| Feb 10, 2025 | 8-K Item 2.02 (results) | $19.92 |
| Nov 26, 2024 | 8-K Item 2.02 (results) | $21.05 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 6, 2024 | 8-K Item 2.02 (results) | — |
| Nov 29, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ARWR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.